ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

A RESEARCH STUDY TO ASSESS THE RITUXIMAB EFFECTS AND SURVIVAL OF THE DIFFUSED LARGE B-CELL LYMPHOMA PATIENTS MANAGED AT TERTIARY CANCER FACILITY

Dr Sameetah Saeed Rana, Dr Bushra Iqbal Puri. Dr. Arsalan Nawaz

Objective: To decide the effect of Rituximab and worldwide prognostic record score on survival in diffuse vast B-cell lymphoma patients. Method: The review examines was directed at Jinnah Hospital, Lahore (January to June 2017) and involved record of patients with diffuse vast B-cell lymphoma. Benchmark worldwide prognostic list score arrange at introduction were noted and the records were isolated into two gatherings An and B based on the sort of chemotherapy. SPSS was utilized for factual investigation. Results: Of the 93 patients in the investigation whose record tables were looked into, 54(58%) were men. Generally speaking middle age was 43 years (go: 18 – 76). Stages at introduction were arranging I 14 (15.1%), organize II 41 (44.1%), organize III 20 (21.5%) and arrange IV 18 (19.4%). Universal prognostic list chance categorization was okay 59 (63.4%), low middle of the road hazard 23 (24.7%), high halfway hazard 10 (10.8%) and high hazard 1 (1.1%). There were 31 (33%) patients in Group An and 62 (67%) in Group B. Middle follow-up was 3.9 years (go: 1.2 – 6.1). Generally speaking survival at 4 years was 66.4%; for Group A 65.3% and for Group B 66.7% (p<0.4). Based on hazard classifications, generally speaking, survival was factually critical (p<0.001) between the gatherings. Conclusion: International prognostic record hazard categorization had a measurably a huge effect on survival. In any case, there was no proof of a huge survival advantage between sorts of chemotherapy. Further controlled preliminaries are required in such a manner. Keywords: Diffuse large B cell lymphoma, Rituximab, Outcome, Survival, Chemotherapy, Extra Nodal.

FULL TEXT